Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives-Reference-Cited by-同舟云学术

Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives

Published:2019-04 Issue:3 Volume:51 Page:292-300
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

Favaloro Emmanuel J.,Mohammed Soma,Curnow Jennifer^ORCID,Pasalic Leonardo

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference17 articles.

1. Anticoagulant therapy: present and future;Favaloro;Semin Thromb Hemost,2015

2. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for Pathology testing;Favaloro;Pathology,2017

3. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges;Favaloro;Curr Drug Metab,2017

4. Pharmacogenetics of vitamin K antagonists: useful or hype?;Lippi;Clin Chem Lab Med,2009

5. Explaining and reducing the variation in inter-laboratory reported values for international normalised ratio;Bonar;Thromb Res,2016

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The utility of the dilute prothrombin time in the interpretation of antiphospholipid syndrome testing;American Journal of Clinical Pathology;2024-05-14

2. New method to differentiate between lupus anticoagulants, progressive coagulation inhibitors and coagulation factor deficiencies in the mixing tests;International Journal of Laboratory Hematology;2024-04-21

3. Testing for the lupus anticoagulant: the good, the bad, and the ugly;Research and Practice in Thrombosis and Haemostasis;2024-03

4. Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome;Rheumatology;2024-02-01

5. A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban;Thrombosis Research;2024-01